PARP1 and neoplasm: Nevertheless, the efficacy of such treatment would probably be greatly improved by combining PARP-1 inhibition with another therapy, as it appears that the use of a PARP-1 inhibitor, niraparib, as a single agent, was not sufficient to observe a correlation between ETS rearrangements and tumour response to treatment in a published clinical trial on sporadic cancers [131].